Renalytix reports FY2023 results: FDA authorization, 55% test growth, $11M cost cuts

Renalytix plc

FDA De Novo marketing authorization for KidneyIntelX.dkd to assess kidney decline risk in diabetic patients.
Over 5,000 KidneyIntelX tests performed in FY2023, up 55% from prior year.
Reduced annual operating expenses by over $11M vs prior year; additional cuts underway.
Completed $20.3M equity financing in February 2023 led by new institutional investors.
Secured multiple insurance contracts including EmblemHealth and CareFirst; over 40 commercial payors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Renalytix plc reported financial results for the fiscal year ended June 30, 2023.

Period: the fiscal year ended June 30, 2023
Result: reported results

Exact text from the filing

Renalytix plc (the “Company”) issued a press release announcing its financial results for the quarter and year ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

Renalytix plc filing history →

Source: SEC EDGAR

accession 0000950170-23-050236

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.